ABM Therapeutics Inc. presented a novel small-molecule, ATP-uncompetitive, phosphorylated MEK (pMEK) inhibitor – ABM-4095 – that potently prevents phosphorylation of MEK by RAF with moderate inhibition of MEK kinase activity; it is being investigated for the potential treatment of pancreatic cancer.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have identified pyrimidine-containing polycyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Kinase inhibitors have emerged as crucial cancer therapeutics due to the involvement of kinases in cancer signaling. At the AACR, Neosome Life Sciences LLC has provided data on their kinase inhibitor NEOS-223 for the potential treatment of tumors. The compound was tested in several cancer cell types, as well as in in vivo cancer models in mice.
Scientists at Nikang Therapeutics Inc. and Shanghai Blueray Biopharma Co. Ltd. have identified tetracyclic derivatives acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Positive updated phase II data with CAN-2409 in pancreatic cancer led shares of Candel Therapeutics Inc. (NASDAQ:CADL) to close April 4 at $6.40, up $4.72, or 281%, well above the firm’s previous 52-week high. At one point during the day, the stock had climbed to $7.65.
Alterome Therapeutics Inc. has closed a $132 million series B financing to support the advancement of its pipeline of next-generation, small-molecule targeted cancer therapies into the clinic, including a highly specific AKT1 E17K inhibitor and a KRAS selective inhibitor.
Grafton Therapeutics Sarl has identified halogenated somatostatin analogues acting as somatostatin SST2 receptor and/or SST5 receptor agonists reported to be useful for the treatment of cancer.
Defence Therapeutics Inc. has announced the successful testing of a second-generation anticancer vaccine, ARM-002, using its lead anticancer molecule Accutox. When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002 led to an 80% complete response when combined with an anti-PD-1 immune-checkpoint inhibitor.
Hyundai Bioscience Corp. is set to become the largest shareholder of ADM Korea Inc., a Seoul, South Korea-based contract research organization (CRO) firm, by purchasing 5.02 million shares for ₩20.4 billion (US$15.5 million) – a 23% stake.
